ARROWHEAD PHARMACEUTICALS IN (ARWR)
US04280A1007 - Common Stock
ARWR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While ARWR seems to be doing ok healthwise, there are quite some concerns on its profitability. ARWR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ARWR has reported negative net income.
In the past year ARWR has reported a negative cash flow from operations.
In the past 5 years ARWR reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ARWR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ARWR (-47.38%) is comparable to the rest of the industry.
ARWR's Return On Equity of -184.99% is on the low side compared to the rest of the industry. ARWR is outperformed by 69.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.38% | ||
| ROE | -184.99% | ||
| ROIC | N/A |
ROA(3y)-24.03%
ROA(5y)-13.77%
ROE(3y)-51.44%
ROE(5y)-28.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARWR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARWR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARWR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARWR has been increased compared to 5 years ago.
There is no outstanding debt for ARWR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 0.31, we must say that ARWR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.31, ARWR is in the better half of the industry, outperforming 61.95% of the companies in the same industry.
There is no outstanding debt for ARWR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.31 |
ROIC/WACCN/A
WACC9.22%
2.3 Liquidity
ARWR has a Current Ratio of 3.73. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ARWR (3.73) is comparable to the rest of the industry.
ARWR has a Quick Ratio of 3.73. This indicates that ARWR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.73, ARWR is in line with its industry, outperforming 43.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 |
3. Growth
3.1 Past
The earnings per share for ARWR have decreased strongly by -88.44% in the last year.
The Revenue for ARWR has decreased by -34.69% in the past year. This is quite bad
The Revenue has been growing by 71.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-88.44%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-217.95%
Revenue 1Y (TTM)-34.69%
Revenue growth 3Y39.85%
Revenue growth 5Y71.76%
Revenue growth Q2Q-94.32%
3.2 Future
ARWR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.13% yearly.
The Revenue is expected to grow by 29.26% on average over the next years. This is a very strong growth
EPS Next Y-41.91%
EPS Next 2Y-18.29%
EPS Next 3Y-7.55%
EPS Next 5Y31.13%
Revenue Next Year-47.25%
Revenue Next 2Y-22.59%
Revenue Next 3Y2.62%
Revenue Next 5Y29.26%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ARWR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARWR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as ARWR's earnings are expected to decrease with -7.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.29%
EPS Next 3Y-7.55%
5. Dividend
5.1 Amount
ARWR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ARROWHEAD PHARMACEUTICALS IN
NASDAQ:ARWR (5/3/2024, 7:00:01 PM)
After market: 24.44 0 (0%)24.44
+0.31 (+1.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.03B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.38% | ||
| ROE | -184.99% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-88.44%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-41.91%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-34.69%
Revenue growth 3Y39.85%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y